Related Experiment Video
Updated: Jan 10, 2026
Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic
Sara S Rinne1, Wen Yin2, Ruonan Li2
1Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.
Abstract:
Overactive epidermal growth factor receptor (EGFR) signaling is often involved in driving different types of carcinomas. It is a well-studied target for targeted therapies, with both monoclonal antibodies and kinase inhibitors available for clinical use. Even though these drugs show a clinical benefit, most patients develop resistance over time. The development of new therapeutic modalities is therefore highly motivated. Herein, we describe a new type of drug candidate targeting EGFR, a so-called affibody-based drug conjugate. It consists of an EGFR-targeting affibody molecule, ZEGFR, expressed as a fusion to an albumin-binding domain for half-life extension, and coupled with the potent cytotoxic drug DM1 via a maleimidocaproyl linker. The resulting drug conjugate ZEGFR-ABD-mcDM1, showed strong binding to recombinant EGFR and EGFR-expressing cells. It was found to be highly potent in killing EGFR-expressing A431 cells with an IC50 of 3.4 nM. In vivo, it showed moderate uptake in A431-derived xenografts with high EGFR expression. Collectively, the results from this study, demonstrate a potent and EGFR-specific drug candidate that holds promise for further development.
Insights
A novel affibody-based drug conjugate targeting epidermal growth factor receptor (EGFR) shows potent anti-cancer activity. This new therapeutic candidate demonstrates promise for overcoming resistance in EGFR-driven carcinomas.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Overactive epidermal growth factor receptor (EGFR) signaling drives various carcinomas.
- Current EGFR-targeted therapies (monoclonal antibodies, kinase inhibitors) face resistance.
- Need for novel therapeutic strategies against EGFR-driven cancers.
Purpose of the Study:
- To develop and characterize a new class of EGFR-targeting drug conjugate.
- To evaluate the efficacy of an affibody-based drug conjugate (Z_EGFR-ABD-mcDM1) in preclinical models.
Main Methods:
- Engineered an affibody molecule (Z_EGFR) fused to an albumin-binding domain (ABD) and conjugated to cytotoxic drug DM1.
- Assessed binding affinity to recombinant EGFR and EGFR-expressing cells.
- Determined in vitro cytotoxicity against A431 cells.
- Evaluated in vivo efficacy in A431 xenograft models.
Main Results:
- The Z_EGFR-ABD-mcDM1 conjugate exhibited strong binding to EGFR.
- Demonstrated high potency in killing EGFR-expressing A431 cells (IC50 = 3.4 nM).
- Showed moderate tumor uptake in vivo in EGFR-expressing xenografts.
Conclusions:
- Z_EGFR-ABD-mcDM1 is a potent and specific EGFR-targeting drug candidate.
- This novel conjugate holds promise for treating EGFR-driven carcinomas.
- Further development is warranted for this new therapeutic modality.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: